AstraZeneca stock falls 1.18% as momentum indicators signal overbought conditions amid profit-taking

Traders Union
All News
Financial News
AstraZeneca slides 1.18% to GBX 14,176

Highlights

AstraZeneca acquired Modella AI to strengthen oncology drug research through deeper AI integration across its R&D teams.
Regulatory approval in China was secured for a cancer therapy co-developed with Hutchmed, and a mid-stage trial for asthma drug atuliflapon was completed.
At the J.P. Morgan Healthcare Conference, AstraZeneca emphasized late-stage drug pipeline growth and reiterated its revenue ambition for 2030.

AI acquisition and China approval drive R&D and growth focus

AstraZeneca has acquired Modella AI to enhance its oncology drug research through further AI integration within its R&D teams. Recent developments also include regulatory approval in China for a cancer therapy co-developed with Hutchmed, the completion of a mid-stage trial for the asthma drug atuliflapon, and the appointment of Joris Silon as the new head of investor relations effective March 1. Additionally, at the J.P. Morgan Healthcare Conference, AstraZeneca underlined its focus on late-stage drug pipeline growth and outlined its revenue ambition for 2030.

Bullish momentum persists despite overbought signals and volatility

AZN remains firmly above all key moving averages, reinforcing a bullish technical setup across all timeframes. The Ichimoku Kijun level at GBX 14,376.18 marks dynamic resistance, with MA-50 serving as robust medium-term support. Momentum indicators, including MACD and ADX, support continued upside, but elevated CCI and Stochastic RSI readings signal overbought conditions. The daily price sits near session lows amid moderate volatility and profit-taking, yet sustained buyer strength keeps downside limited.

Upside bias holds with volatility band defining near-term risk

In the short term, AZN is expected to consolidate within a volatility band between GBX 13,800.00 and GBX 14,900.00. There is a strong probability (over 80%) of further upside supported by consistent weekly Buy signals across RSI, ADX, MACD, and MA-50. Should the price decisively break above GBX 14,900.00, additional gains may follow, while a move below GBX 13,800.00 could trigger a sharper pullback toward MA-50 support.

Anton Kharitonov, analyst at Traders Union, sees AstraZeneca’s technical picture as bullish but overextended in the short term. Strong news around AI integration and late-stage pipeline growth have kept sentiment resilient. However, the analyst stays alert to overbought signals and the risk of profit-taking. "If GBX 13,800.00 fails to hold, I expect a sharper correction toward MA-50 — so I remain cautious at these levels."

Last time, analysts noted that AstraZeneca PLC was exhibiting a strong bullish trend, with its price firmly above all major moving averages and supported by positive momentum indicators such as RSI, MACD, and ADX. Dynamic support and resistance are defined near the Ichimoku Kijun and upper price bands, while short-term oscillators signal mixed overbought conditions amid moderate to high volatility and persistent upside bias.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.